A randomised, double-blinded, placebo-controlled study on the efficacy of a unique extract of green-lipped mussel (Perna canaliculus) in horses with chronic fetlock lameness attributed to osteoarthritis

Equine Veterinary Journal

Volumn 44, Issue 4, 2012, Pages 393-398

  Cayzer, J ^a   Hedderley, D ^b   Gray, S ^c  

^a MASSEY UNIVERSITY   (New Zealand)

^b THE NEW ZEALAND INSTITUTE FOR PLANT AND FOOD RESEARCH LIMITED   (New Zealand)

^c Samantha Gray Consulting   (New Zealand)

Author keywords

Biolane; Degenerative joint disease; Green lipped mussel; Horse; Lameness; Osteoarthritis; Perna canaliculus

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; TISSUE EXTRACT;

ANIMAL; ANIMAL DISEASE; ANIMAL LAMENESS; ARTICLE; CHEMISTRY; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FORELIMB; HORSE; HORSE DISEASE; MALE; OSTEOARTHRITIS; PERNA; RANDOMIZED CONTROLLED TRIAL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; FORELIMB; HORSE DISEASES; HORSES; LAMENESS, ANIMAL; MALE; OSTEOARTHRITIS; PERNA; TISSUE EXTRACTS;

EQUIDAE; PERNA; PERNA CANALICULUS;

EID: 84862022083     PISSN: 04251644     EISSN: 20423306     Source Type: Journal    
DOI: 10.1111/j.2042-3306.2011.00455.x     Document Type: Article

References (28)

1. Audeval, B. and Bouchacourt, P. (1986) Double-blind placebo-controlled study of the mussel Perna canaliculus (New Zealand green-lipped mussel) in gonoarthrosis (arthritis of the knee). La Gazette Medicale 93, 111-115.
2. Brien, S., Prescott, P., Coghlan, B., Bashir, N. and Lewith, G. (2008) Systematic review of the nutritional supplement Perna Canaliculus (green-lipped mussel) in the treatment of osteoarthritis. QJM 101, 167-179.
3. Cheras, P.A., Stevenson, L. and Myers, S.P. (2005) Vascular mechanisms in osteoarthritis: rationale for treatment with a marine-based complementary medicine. Osteoarthr. Cartil. 13, S95.
4. Cobb, C.S. and Ernst, E. (2006) Systematic review of a marine nutriceutical supplement in clinical trials for arthritis: the effectiveness of the New Zealand green-lipped mussel Perna canaliculus. Clin. Rheumatol. 25, 275-284.
5. de Grauw, J.C., van de Lest, C.H.A., Brama, P.A.J., Rambags, B.P.B. and van Weeren, P.R. (2009) In vivo effects of meloxicam on inflammatory mediators, MMP activity and cartilage biomarkers in equine joints with acute synovitis. Equine vet. J. 41, 693-699.
6. Du, J., White, N. and Eddington, N.D. (2004) The bioavailability and pharmacokinetics of glucosamine hydrochloride and chondroitin sulfate after oral and intravenous single dose administration in the horse. Biopharm. Drug Dispos. 25, 109-116.
7. Eddington, N.D., Du, J. and White, N. (2001) Evidence of the oral absorption of chondroitin sulfate as determined by total disaccharide content after oral and intravenous administration to horses. Proc. Am. Ass. equine Practnrs. 47, 326-328.
8. European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies, (NDA). (2009) Scientific Opinion on the substantiation of health claims related to green lipped mussel extract and maintenance of joints, bone and mucles (ID 1571, 1813) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 on request from the European Commission. EFSA J. 7, 1265-1279.
9. Gibson, R.G., Gibson, S.L., Conway, V. and Chappell, D. (1980) Perna canaliculus in the treatment of arthritis. Practitioner 224, 955-960.
10. Hills, M. and Armitage, P. (1979) The two period cross-over clinical trial. Br. J. Clin. Pharmacol. 8, 7-20.
11. Keegan, K.G., Dent, E.V., Wilson, D.A., Janicek, J., Kramer, J., Lacarrubba, A., Walsh, D.M., Cassells, M.W., Esther, T.M., Schiltz, P., Frees, K.E., Wilhite, C.L., Clark, J.M., Pollitt, C.C., Shaw, R. and Norris, T. (2010) Repeatability of subjective evaluation of lameness in horses. Equine vet. J. 42, 92-97.
12. Kendall, R.V., Lawson, J.W. and Hurley, L.A. (2000) New research and a clinical report on the use of Perna canaliculus in the management of arthritis. Townsend Letter for Doctors & Patients July, 99-111.
13. Koene, M., Goupil, X., Kampmann, C., Hanson, P.D., Denton, D. and Pollmeier, M.G. (2010) Field trial validation of the efficacy and acceptability of Firocoxib, a highly selective Cox-2 inhibitor, in a group of 96 lame horses. J. Equine Vet, Sci. 30, 237-243.
14. Kester, W.O. (1991) Definition and classification of lameness. In: Guide for Veterinary Services and Judging of Equestrian Events, 4th edn. American Association of Equine Practitioners, Lexington. p 19.
15. Kvaternick, V., Pollmeier, M., Fischer, J. and Hanson, P.D. (2007) Pharmacokinetics and metabolism of orally administered firocoxib, a novel second generation coxib, in horses. J. vet. Pharmacol. Therap. 30, 208-217.
16. McIlwraith, C.W. and Vachon, A. (1988) Review of pathogenesis and treatment of degenerative joint disease. Equine vet. J., Suppl. 6, 3-11.
17. Moher, D., Hopewell, S., Schulz, K.F., Montori, V., Gøtzsche, P.C., Devereaux, P.J., Elbourne, D., Egger, M. and Altman, D.G. (2010) CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 340, c869.
18. Pearson, W. (2003) Ethnoveterinary medicine: the science of botanicals in equine health and disease. In: Proceedings of the 2nd European Equine Health & Nutrition Congress. Lelystad, The Netherlands. pp 31-40.
19. Pearson, W. and Lindinger, M. (2009) Low quality evidence for glucosamine-based nutraceuticals in equine joint disease: review of in vivo studies. Equine vet. J. 41, 706-712.
20. Piepho, H. and Kalka, E. (2003) Threshold models with fixed and random effects for ordered categorical data. Food Qual. Prefer. 14, 343-357.
21. Pollard, B., Guilford, W.G., Ankenbauer-Perkins, K.L. and Hedderley, D. (2006) Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease. N. Z. vet. J. 54, 114-118.
22. Rainsford, K.D. and Whitehouse, M.W. (1980) Gastroprotective and anti-inflammatory properties of green lipped mussel (Perna canaliculus) preparation. Arzneim Forsch/Drug Res. 30, 2128-2132.
23. Rossdale, P.D., Hopes, R., Digby, N.J. and Offord, K. (1985) Epidemiological study of wastage among racehorses 1982 and 1983. Vet. Rec. 116, 66-69.
24. Sainani, K.L. (2010) Making sense of Intention-to-treat. PM R. 2, 209-213.
25. Schulz, K.F., Altman, D.G. and Moher, D. for the CONSORT Group. (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 698-702.
26. Senn, S. (2002) Cross-over Trials in Clinical Research, 2nd edn., John Wiley and Sons Ltd, England.
27. Todhunter, R.J. (1992) Synovial joint anatomy, biology and pathobiology. In: Equine Surgery, Ed: J.A. Auer, W.B.Saunders, Philadelphia. pp 844-866.
28. Troy, D.B. (2006) Remington: The Science and Practice of Pharmacy, 21st edn., Lippincott Williams & Wilkins, Philadelphia. pp 965-975.